Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8727)	4/7/2001 6:52:46 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 9719

Peter and Rick, Thanks for your responses. I find the research in this area fascinating(even with the ups and downs of Entremed). I realize any funding for a small biotech is "better than a sharp stick in the eye", but I wasn't sure of the difficulty in getting such NIH grants. In my industry we have the "who knows who" method of getting grants allocated, in many cases. This is the news release about the particular grant that I refer:InKine Scientist Awarded NIH Grant to Study Angiocidin as an Inhibitor of Angiogenesis BLUE BELL, Pa., Apr 5, 2001 (BW HealthWire) -- InKine Pharmaceutical Company, Inc. (NASDAQ: INKP chart, msgs) today announced that Dr. George Tuszynski, Professor of Surgery and Pathology at MCP Hahnemann University and a founding scientist of InKine, was awarded a four year, National Institutes of Health (NIH) grant for funding of over one million dollars. This multi-year grant will support Dr. Tuszynski's continuing research efforts toward understanding how certain compounds, such as InKine's drug candidate Angiocidin, inhibit thrombospondin-1 (TSP-1), a human hormone that may prevent and inhibit angiogenesis in tumors. Dr. Tuszynski has demonstrated that Angiocidin, when injected intravenously into animals bearing Lewis Lung carcinoma, inhibited the growth of tumors by more than 500% as compared to a buffer control. It is believed that Angiocidin exerts its anti-antigenic activity by competing with TSP-1. "We are thrilled that Dr. Tuszynski's novel approach towards the treatment of cancer was recognized by the NIH, as evidenced by the funding of this extensive grant," said Leonard S. Jacob, M.D., Ph.D., Chairman and CEO of InKine. "We have high expectations that his approaches toward the treatment of cancer, with compounds such as Angiocidin, will lead to a variety of new therapeutic drugs to treat several types of cancer." InKine has the rights to all the U.S. and foreign patents and patent applications relating to the thrombospondin technology, Angiocidin, and all future research and development of the thrombospondin technology conducted in Dr. Tuszynski's laboratory, through a license with MCP Hahnemann University. About InKine Pharmaceutical InKine Pharmaceutical Company, Inc. is a publicly traded biopharmaceutical company focused on the diagnosis and treatment of cancer and autoimmune diseases. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. Support of early-stage product opportunities comes through its university-based sponsored research. The Company's first product, Visicol(TM), was launched in January 2001 and is the first and only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's portfolio also includes three late-stage product candidates, IBStat(TM) in development for the treatment of spasm in the colon, Hematrol(TM), in Phase III trials for the treatment of idiopathic thrombocytopenic purpura and Colirest(TM), advancing to pivotal clinical trials for the treatment of Crohn's disease. In addition, the Company is developing preclinical compounds from its two platform technologies, including Angiocidin(TM), a potent and specific angiogenesis inhibitor for potential use in cancer patients. For further information, please visit InKine on their web site inkine.com.